Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer

Patel, Dilan; Ji, Xi; Luo, Jingqin; Hassan, Bilal; Thomas, Shana; Cynthia, X.; Campian, Jian

doi:10.1007/s10549-018-05106-7

Cited by 57 publications

(61 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies (n = 18; 78%) included patients with all BC molecular subtypes [32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48]. four included only patients withTNBC [49][50][51][52], and one work included patients with onlyhormone receptor-negative BC (independently of the HER2 status) [53]. The NLR cut-off for the statistical analyses, computed by the ROC curves analysis in 78% of these studies, was between 1.34 and 4.…”

Section: Results On Other Inflammatory Blood Markersmentioning

confidence: 99%

“…Studies including Specific BC Molecular Subtypes: four studies assessed OS in the function of the NLR in patients with TNBC [49][50][51][52]. Three (75%) showed that a high NLR was correlated with a shorter OS (univariate analysis) [49][50][51].…”

Section: Results On Nlr and Os And Bcssmentioning

confidence: 99%

“…Among the four studies on lymphocyte count and survival [33,44,47,52], only one (25%) found that lymphocyte count was correlated with DFS and DSS [44], but never with OS. No multivariate analysis was performed.…”

Section: Results On Other Inflammatory Blood Markersmentioning

confidence: 99%

See 2 more Smart Citations

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review

Corbeau

Jacot

Guiu

2020

Cancers

View full text Add to dashboard Cite

Inflammatory blood markers (IBM), such as the neutrophil to lymphocyte ratio (NLR), have emerged as potential prognostic factors in various cancers, including breast cancer (BC), potentially allowing an easy, minimally invasive evaluation of a given cancer‘s prognosis and treatment outcome. We report here a systematic overview of the published data evaluating NLR as a prognostic factor or predictive factor for pathological complete response (PCR) and toxicity in early and advanced BC. A total of 45 articles were identified. NLR was found to be an independent prognostic factor for survival in most of the adjuvant treatment studies. However, no significant correlation was found between survival and NLR for early BC patients receiving neo-adjuvant chemotherapy (NACT) and advanced BC patients. Most studies failed to find a significant correlation between NLR and PCR after NACT. Finally, some data showed that IBM could be predictive of chemotherapy-related toxicity.

show abstract

Section: Results On Other Inflammatory Blood Markersmentioning

confidence: 99%

Section: Results On Nlr and Os And Bcssmentioning

confidence: 99%

See 1 more Smart Citation

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review

Corbeau

Jacot

Guiu

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Moreover, NACT has become the standard treatment for locally advanced breast cancer, and the quality of life and clinical outcomes for these patients have largely improved. 26 Therefore, it is of importance to search accurate indicator for choosing the optimal treatment regimen and improving clinical outcomes.…”

Section: Discussionmentioning

confidence: 99%

<p>Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator</p>

Chen¹,

Kong²,

Wang³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background and Objective: Systemic inflammation response index (SIRI=N×M/L), based on neutrophil (N), monocyte (M), and lymphocyte (L) counts, is used to predict the survival of patients with malignant tumors and can fully evaluate the balance between host immune and inflammatory condition. The present study is aimed to evaluate the potential prognostic significance of SIRI in patients with breast cancer undergoing neoadjuvant chemotherapy. Subjects and Methods: A total of 262 breast cancer patients treated with neoadjuvant chemotherapy were enrolled in this retrospective study. The optimal cutoff value of SIRI by receiver operating characteristic curve stratified patients into low SIRI (<0.85×10 9 /L) group and high SIRI (≥0.85×10 9 /L) group. The associations between breast cancer and clinicopathological variables by SIRI were determined by chi-square test or Fisher's exact test. Kaplan-Meier plots and log-rank test were used to evaluate the clinical outcomes of disease-free survival (DFS) and overall survival (OS). Univariate and multivariate Cox proportional hazards regression models were used to analyze the prognostic value of SIRI. The toxicity of neoadjuvant chemotherapy was evaluated by the National Cancer Institute Common Toxicity Criteria (NCICTC). Results: The results were shown that SIRI had prognostic significance by optimal cutoff value of 0.85×10 9 /L on DFS and OS in univariate and multivariate Cox regression survival analyses. Compared with patients who had high SIRI, patients with low SIRI had longer DFS and OS (41.27 vs 30.45 months, HR: 1.694, 95% CI: 1.128-2.543, P=0.011; 52.86 vs 45.75 months, HR: 1.288, 95% CI: 0.781-3.124, P=0.002, respectively). The patients with low SIRI had better 3-, 5-, and 10-year rates of DFS and OS than those with high SIRI. The common toxicities after neoadjuvant chemotherapy were hematologic and gastrointestinal reaction, and the SIRI had no significance on toxicities of all enrolled patients, excepted diarrhea. In patients without neural invasion, those with low SIRI had better prognosis and lower recurrence rates than those with high SIRI.Conclusion: Pretreatment SIRI with the advantage of repeatable, convenient, and non-invasive is a useful prognostic indicator for breast cancer patients who received neoadjuvant chemotherapy and is a promising biomarker for breast cancer on treatment strategy decisions.

show abstract

“…The incidence of breast carcinoma is increasing rapidly in coastal developed cities, and the post‐menopausal breast cancer patients in China will reach 100/100 000 in the future . Because of the progress of early diagnosis and the improvement of treatment strategy, lots of patients have been successfully treated, and the average 5‐year survival rate is around 90% . However, approximately 20%‐25% patients are diagnosed with locally advanced breast cancer, and these patients account for early relapse and deaths .…”

Section: Introductionmentioning

confidence: 99%

Pre‐treatment systemic immune‐inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy

Chen

Kong

Wang

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

The systemic immune‐inflammation index (SII = N × P/L) based on neutrophil (N), platelet (P) and lymphocyte (L) counts is used to predict the survival of patients with malignant tumours and can fully reflect the balance between host inflammatory and immune status. This study is conducted to explore the potential prognostic significance of SII in patients with breast cancer undergoing neoadjuvant chemotherapy (NACT). A total of 262 patients with breast cancer received NACT were enrolled in this study. According to the receiver operating characteristic curve, the optimal cut‐off value of SII was divided into two groups: low SII group (<602 × 109/L) and high SII group (≥602 × 109/L). The associations between breast cancer and clinicopathological variables by SII were determined by chi‐squared test or Fisher's exact test. The Kaplan‐Meier plots and log‐rank test were used to determine clinical outcomes of disease‐free survival (DFS) and overall survival (OS). The prognostic value of SII was analysed by univariate and multivariate Cox proportional hazards regression models. The toxicity of NACT was accessed by National Cancer Institute Common Toxicity Criteria (NCICTC). According to univariate and multivariate Cox regression survival analyses, the results showed that the value of SII had prognostic significance for DFS and OS. The patients with low SII value had longer DFS and OS than those with high SII value (31.11 vs 40.76 months, HR: 1.075, 95% CI: 0.718‐1.610, P = .006; 44.47 vs 53.68 months, HR: 1.051, 95% CI: 0.707‐1.564, P = .005, respectively). The incidence of DFS and OS in breast cancer patients with low SII value was higher than that in those patients with high SII value in 3‐, 5‐ and 10‐year rates. The common toxicities after NACT were haematological and gastrointestinal reaction, and there were no differences by SII for the assessment of side effects of neoadjuvant chemotherapy. Meanwhile, the results also proved that breast cancer patients with low SII value and high Miller and Payne grade (MPG) survived longer than those breast cancer with high SII value and low MPG grade. In patients without lymph vessel invasion, these breast cancer patients with low SII value had better prognosis and lower recurrence rates than those with high SII value. Pre‐treatment SII with the advantage of reproducible, convenient and non‐invasive was a useful prognostic indicator for breast cancer patients undergoing neoadjuvant chemotherapy and is a promising biomarker for breast cancer on treatment strategy decisions.

show abstract

Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer

Cited by 57 publications

References 35 publications

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review

<p>Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator</p>

Pre‐treatment systemic immune‐inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy

Contact Info

Product

Resources

About